Fresenius Group Overview

December 22, 2016

Fresenius Helios receives antitrust approval to acquire Quirónsalud

  • No conditions by Spanish antitrust authority
  • Closing of transaction expected by January 31, 2017

Fresenius Helios today received antitrust approval to acquire Quirónsalud, Spain’s largest private hospital operator. The relevant Spanish antitrust authority has approved the transaction without imposing conditions. The acquisition can therefore be closed by January 31, 2017. Quirónsalud will be consolidated as of February 1, 2017.

Quirónsalud’s network is comprised of 43 hospitals, 39 outpatient centers and around 300 Occupational Risk Prevention (“ORP”) centers located in all economically important areas in Spain. The company has about 35,000 employees and offers the full spectrum of inpatient and outpatient care. With the acquisition, Fresenius Helios strengthens its position as Europe’s largest private hospital operator.

Given the expected meaningful accretion to Group sales and earnings, Fresenius will publish new mid-term targets as part of its full-year 2016 reporting.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.